Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00274859
First received: January 10, 2006
Last updated: July 23, 2008
Last verified: May 2007

January 10, 2006
July 23, 2008
August 2005
Not Provided
Objective response rate [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00274859 on ClinicalTrials.gov Archive Site
  • Clinical benefit [ Designated as safety issue: No ]
  • Tolerability [ Designated as safety issue: Yes ]
  • Progression-free [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer
Multicenter Phase II Study Evaluating Gemcitabine and Oxaliplatin in the Treatment of Patients Suffering From Metastatic Breast Cancer Who Are Not Candidates For Treatment With Antracyclines and Taxanes

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving gemcitabine together with oxaliplatin works in treating patients with metastatic cancer who cannot receive anthracycline or taxane therapy.

OBJECTIVES:

Primary

  • Determine the objective response rate in patients with metastatic cancer not amenable to anthracycline or taxane therapy treated with gemcitabine hydrochloride and oxaliplatin.

Secondary

  • Determine the clinical benefit and tolerability of this regimen in these patients.
  • Determine the progression-free and overall survival of patients treated with this regimen.

OUTLINE: This is an open-label, multicenter study.

Patients receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study.

Interventional
Phase 2
Masking: Open Label
Primary Purpose: Treatment
Unspecified Adult Solid Tumor, Protocol Specific
  • Drug: gemcitabine hydrochloride
  • Drug: oxaliplatin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
45
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically confirmed cancer

    • Metastatic disease
  • Measurable metastatic disease ≥ 1 cm by spiral CT scan and/or cutaneous lesion ≥ 2 cm
  • Not a candidate for anthracycline or taxane chemotherapy
  • No brain metastases

PATIENT CHARACTERISTICS:

  • ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
  • Life expectancy > 12 weeks
  • Neutrophil count > 1,000/mm^3
  • Platelet count > 100,000/mm^3
  • Alkaline phosphatase < 5 times upper limit of normal (ULN)
  • Bilirubin < 1.5 times ULN
  • Creatinine < 1.5 times ULN OR creatinine clearance > 30 mL/min
  • SGOT and SGPT < 3 times ULN (5 times ULN if liver metastases present)
  • No pre-existing neuropathy
  • Not pregnant or nursing
  • No uncontrolled hypercalcemia
  • No familial, social, geographical, or psychological condition that would preclude study treatment
  • No other malignancy that is not considered cured

PRIOR CONCURRENT THERAPY:

  • No prior chemotherapy for metastatic disease, including anthracyclines or taxanes
  • Prior hormonal therapy allowed
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00274859
CDR0000454320, GERCOR-SEGEMOX-S04-1, LILLY-GERCOR-SEGEMOX-S04-1, SANOFI-GERCOR-SEGEMOX-S04-1, EU-20571
Not Provided
Not Provided
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Not Provided
Study Chair: Joseph Gligorov, MD Hopital Tenon
National Cancer Institute (NCI)
May 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP